1THSTI-IAVI HIV Vaccine Design Program, Translational Health Science and Technology Institute, Faridabad-121001, Haryana, India.
2International AIDS Vaccine Initiative, New York, USA.
J Gen Virol. 2018 Oct;99(10):1438-1443. doi: 10.1099/jgv.0.001141. Epub 2018 Aug 21.
Human immunodeficiency virus 1 (HIV-1) diversity is a significant challenge in developing a vaccine against the virus. B/C recombinants have been found in India and other places but are the predominant clade prevalent in China. HIV-1 envelopes (Envs) are the target of broadly neutralizing antibodies (bNAbs) which develop spontaneously in some HIV-1 infected patients. It has been previously reported with efficiently cleaved clade A, B and C Envs that preferential binding of Envs to bNAbs as opposed to non-NAbs, a desirable property for immunogens, is correlated with efficient cleavage of the Env precursor polypeptide into constituent subunits. These Envs are suitable for designing immunogens as soluble proteins, virus-like particles or for delivery by viral vectors/plasmid DNA. However, a B/C recombinant Env with similar properties has not been reported. Here we show that the chimeric, recombinant B/C clade Env LT5.J4b12C is efficiently cleaved on the plasma membrane and selectively binds to bNAbs.
人类免疫缺陷病毒 1（HIV-1）多样性是开发针对该病毒疫苗的重大挑战。在印度和其他地方发现了 B/C 重组体，但在中国，主要流行的是 B/C 重组体。HIV-1 包膜（Env）是广泛中和抗体（bNAb）的靶标，这些 bNAb 会在一些 HIV-1 感染的患者中自发产生。此前有报道称，对于有效切割的 A、B 和 C Env，Env 与 bNAb 的优先结合，而不是与非 bNAb 的结合，这是免疫原的理想特性，与 Env 前体多肽有效切割成组成亚单位有关。这些 Env 适合设计成可溶性蛋白、病毒样颗粒或通过病毒载体/质粒 DNA 进行递送。然而，尚未报道具有类似特性的 B/C 重组 Env。在这里，我们展示了嵌合的、重组的 B/C 重组体 Env LT5.J4b12C 在质膜上被有效切割，并选择性地与 bNAb 结合。
